Hayashi H, Maeda M, Murakami S, Kumagai N, Chen Y, Hatayama T, Katoh M, Miyahara N, Yamamoto S, Yoshida Y, Nishimura Y, Kusaka M, Fujimoto W, Otsuki T
Department of Hygiene, Kawasaki Medical School, Kurashiki, Japan.
Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):53-62. doi: 10.1177/039463200902200107.
Silicosis patients (SILs) possess not only respiratory disorders but also alterations in autoimmunity. To determine an early indicator of immunological disturbance in SILs, the role of serum-soluble interleukin (IL)-2 receptor (sIL-2R) was analyzed. Of ten SILs, immunological clinical parameters such as immunoglobulin (Ig) G, complements, the titer of autoantibodies including anti-nuclear antibodies (ANA), anti-Scl-70 antibody (Ab) and anti-centromere (CM) Ab, and experimental indicators such as serum-soluble Fas, serum IL-2, CD25+ cells in CD4+ or CD8+ fractions, and sIL-2R were divided from respiratory parameters such as percent vital capacity (%VC), percentage of forced expiratory volume in 1 second (FEV1.0%) and v25/Ht (liter/second/m(body height) by a correlation assay. Additionally, a stepwise regression test showed that sIL-2R was correlated with Ig G, ANA and anti-CM Ab. Furthermore, factor analysis revealed that sIL-2R contributed to the subpopulation of SILs with poorer immunological status in the absence of alterations in respiratory status. By defining healthy donors as 1, SILs as 2 and patients with systemic sclerosis as 3 for immunopathological progression status as metric variables, sIL2R and ANA showed a strong positive correlation. This suggests that sIL-2R is a good clinical indicator of immunological disturbance found in SILs without clinical manifestations of any disturbance in autoimmunity. Further analysis using a large-scale number of patients should be performed to confirm these findings.
矽肺患者不仅患有呼吸系统疾病,自身免疫也存在改变。为了确定矽肺患者免疫紊乱的早期指标,分析了血清可溶性白细胞介素(IL)-2受体(sIL-2R)的作用。在10名矽肺患者中,通过相关性分析,将免疫球蛋白(Ig)G、补体、包括抗核抗体(ANA)、抗Scl-70抗体(Ab)和抗着丝点(CM)Ab在内的自身抗体滴度等免疫临床参数,以及血清可溶性Fas、血清IL-2、CD4+或CD8+亚群中的CD25+细胞和sIL-2R等实验指标,与肺活量百分比(%VC)、一秒用力呼气量百分比(FEV1.0%)和v25/Ht(升/秒/米(身高))等呼吸参数区分开来。此外,逐步回归测试表明sIL-2R与Ig G、ANA和抗CM Ab相关。此外,因子分析显示,在呼吸状态无改变的情况下,sIL-2R有助于识别免疫状态较差的矽肺亚群。将健康供体定义为1、矽肺患者定义为2、系统性硬化症患者定义为3作为免疫病理进展状态的度量变量,sIL2R和ANA显示出强烈的正相关。这表明sIL-2R是矽肺患者免疫紊乱的良好临床指标,且这些患者无自身免疫紊乱的临床表现。应使用大量患者进行进一步分析以证实这些发现。